CompletedPhase 2

Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)

Belgium143 participantsStarted 2014-09

Plain-language summary

The purpose of this study is to establish the effectiveness of the combined drug approach (anti-thrombin III, infliximab, apotransferrin, human recombinant erythropoietin beta, C1-inhibitor, glutathione, alfa-tocopherol, melatonin and epoprostenol)aimed to reduce ischemia-reperfusion injury during liver transplantation in eligible recipients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients suffering from irreversible liver failure eligible for liver transplantation according to Eurotransplant guidelines.
✓. Patients \> 18 years of age at time of listing on Eurotransplant waiting list for liver transplantation in University Hospitals Leuven, Belgium.

Exclusion criteria

✕. Patients who refuse to participate in the study.
✕. History of hypersensitivity to one/several component(s) of the combined drug approach.
✕. Conditions that prevent the use of the combined drug approach:
✕. Mental conditions rendering the subject incapable to understand the nature, scope, and consequences of the trial.
✕. Combined organ transplantation.
✕. Re-transplantation.
✕. Patients that are dialysis-dependent prior to the liver transplantation.

What they're measuring

Peak Aspartate Aminotransferase Within First 72h Post Transplant

Timeframe: within 72 hours following liver transplantation

Trial details

NCT IDNCT02251041

SponsorUniversitaire Ziekenhuizen KU Leuven

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-02

Results submitted2023-07-14

View on ClinicalTrials.gov More Reperfusion Injury trials